2,3-Dihydroindole Compounds for D4 and 5-HT2A Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dopamine D4 and 5-HT2A receptor ligands suffer from poor oral bioavailability and short half-lives due to rapid hepatic clearance, limiting their therapeutic effectiveness in treating psychiatric and neurologic disorders.
Innovation Solution
Development of novel 2,3-dihydroindole compounds with specific structural modifications that act as partial agonists or antagonists at the dopamine D4 and 5-HT2A receptors, optimizing their pharmacokinetic profile for improved bioavailability and longer half-lives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing dopamine D4 and 5-HT2A receptor ligands are used, then therapeutic effects are achieved, but oral bioavailability is poor and half-lives are short due to rapid hepatic clearance
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of the ligands through various substitutions at specific positions (R1-R12) of the dihydroindole core. These structural parameter changes alter the pharmacokinetic properties, specifically reducing hepatic clearance rate and extending half-life while maintaining therapeutic effectiveness at dopamine D4 and 5-HT2A receptors
2Reliability
If existing dopamine D4 and 5-HT2A receptor ligands are used, then therapeutic effects are achieved, but oral bioavailability is poor due to rapid hepatic clearance
Solution Approach 1:
The patent employs parameter changes by introducing specific substituents and structural modifications to the ligand molecules. These changes optimize the balance between lipophilicity and metabolic stability, thereby improving oral bioavailability while preserving the therapeutic action at dopamine D4 and 5-HT2A receptors
3Duration of action of moving object
If structural modifications are made to improve pharmacokinetic profile, then bioavailability and half-life are improved, but compound complexity increases
Solution Approach 1:
The patent applies local quality by making targeted, localized modifications at specific positions (R1-R12) of the dihydroindole core structure rather than进行全面 restructuring. Each substitution is strategically placed to optimize pharmacokinetic properties while maintaining the essential pharmacophore features, thus improving half-life without excessive complexity
Data Source
AI summary
The invention relates to compounds of the formula Iwherein the variables are as defined in the claims. The compounds are useful in the treatment of a disease where a D4 receptor and/or a 5-HT2A receptor is implicated.